Has Usman Tahir, MD received payments from drug or device companies?

Yes. Drug and device makers reported $451 in general payments to Usman Tahir, MD across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Usman Tahir, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Usman Tahir, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Usman Tahir, MD

Internal Medicine · Indianapolis, INNPI 1306003348

Payments from drug & device makers

$451in general payments, 2019–2025

Across 22 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$144
Grifols USA, LLC$108
Boston Scientific$56
Johnson & Johnson$51
Philips North America LLC$33
AstraZeneca$32
plus $27 from 2 others

What the payments were for

Food & beverage$451100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	6	$144
Grifols USA, LLC	5	$108
Boston Scientific	1	$56
Johnson & Johnson	4	$51
Philips North America LLC	2	$33
AstraZeneca	2	$32
Tetraphase Pharmaceuticals, Inc.	1	$16
Circassia Inc.	1	$11

How this compares

$451 in reported general payments places this provider in the 60th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana →

Medicare billing

Part B allowed, 2024

$103,456

Medicare patients

386

Services billed

1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Midodrine Hcl	17	$1,416
Naloxone Hcl	12	$571
Hydralazine Hcl	32	$300
Amlodipine Besylate	47	$225
Torsemide	17	$207
Atorvastatin Calcium	19	$164
Pantoprazole Sodium	16	$109
Tamsulosin Hcl	12	$74
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	15	$57
Potassium Chloride	15	$52
Oxycodone Hcl	11	$38
Cephalexin	12	$37
Prednisone	13	$21

Paid to pharmacies, not to this prescriber.

Other internal medicine in Indianapolis

Raj VuppalanchiIndianapolis$3.4M
Phillip TothIndianapolis$3.2M
Georgiann LinnemeierIndianapolis$692K
Allon FriedmanIndianapolis$524K
Eromonsele IdahosaIndianapolis$471K
Misty ShieldsIndianapolis$411K
Pei LuIndianapolis$298K
Paul DexterIndianapolis$161K
Jon DukeIndianapolis$138K
Napoleon MamintaIndianapolis$116K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →